News

EU partners with billionaire
Enlarge image

FundingEU

EU partners with billionaire

11.06.2013 - Bill Gates and EU Research Commissioner Máire Geoghegan-Quinn have signed a partnership to fight neglected diseases.

The multibillion partnership of the Bill & Melinda Gates Foundation and the European Commission aims at fighting and other poverty-related diseases such as HIV/AIDS, tuberculosis malaria, lymphatic filariasis or sleeping sickness, which affect more than one billion people globally.
"The foundation is completely committed to supporting efforts to develop life-saving products to help solve some of the world’s toughest problems“, said Gates. The partnership will develop at least one improved product per year, according to Geoghegan-Quinn.

Much of the work will be carried out through the European and Developing Countries Clinical Trials Partnership (EDCTP), which so far involves 16 European and 30 sub-Saharan African countries. The European Commission has proposed funding of up to €1 bn from the EU budget to match the contributions of the European partner countries.

Between 2007 and 2011, Gates and the EU invested around €2.4bn in R&D on neglected infectious diseases. Under the agreement, the partners will develop new drugs, vaccines and diagnostics suited to the needs of the population of poor countries , improve health systems and ensure the delivery of such products. Furthermore, the Gates Foundation and the Commission will launch a joint innovation prize in 2014 in order to honour current approaches to global health.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/eu-partners-with-billionaire.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • MAGFORCE6.50 EUR20.4%
  • LONZA101.10 CHF9.2%
  • SANTHERA74.95 CHF7.8%

FLOP

  • WILEX2.22 EUR-32.3%
  • VITA 343.78 EUR-20.1%
  • MOLOGEN7.80 EUR-17.5%

TOP

  • SANTHERA74.95 CHF3556.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.40 EUR185.7%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014